Phase 3RecruitingAge-related condition
A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection
A Multicenter Phase III Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection
- Sponsor
- HTA Co., Ltd. (Industry)
- Enrollment
- 400 planned
- Conditions
- Mild Cognitive Impairment (MCI); Alzheimer's Disease (AD)
- Interventions
- [18F]Fluorbetazine injection
- Ages
- adults, older adults
- Registry
- NCT07764679
Full record on ClinicalTrials.gov
From the registry
A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using \[18F\]Fluorbetazine injection.
Primary outcomes
- The sensitivity and specificity of PET imaging visual interpretation results compared to true standards after a single intravenous injection of [18F]Fluorbetazine injection in participants with AD induced MCI, AD dementia and normal cognitive.
History
Study completion expected
Primary completion expected
Registered
Started